ABBVIE INC. vs. TG Therapeutics, Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| ABBV | TGTX | |
|---|---|---|
| Market Cap | $439.59 billion | $7.58 billion |
| Revenue (TTM) | $64.39 billion | $799.54 million |
| Net Income (TTM) | $6.32 billion | $441.49 million |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | TGTX | |
|---|---|---|
| P/E Ratio | 70.47 | 17.72 |
| Price / Book | -74.66 | 12.54 |
| Price / Sales | 6.83 | 9.48 |
ABBV leads on 2 of 3 valuation factors.
Profitability
| ABBV | TGTX | |
|---|---|---|
| Net Margin | 9.81% | 55.22% |
| Return on Equity | -107.29% | 73.08% |
TGTX leads on 2 of 2 profitability factors.
Dividend
| ABBV | TGTX | |
|---|---|---|
| Dividend Yield | 2.77% | — |
| Payout Ratio | 195.48 | — |
ABBV and TGTX split the dividend factors evenly.
Risk & Sentiment
| ABBV | TGTX | |
|---|---|---|
| Short Interest | 0.85% | 11.01% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, TGTX overview, TGTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.